RT Journal Article
SR Electronic
T1 Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.22.21259893
DO 10.1101/2021.07.22.21259893
A1 Wei-Yu Lin
A1 Sarah E Fordham
A1 Eric Hungate
A1 Nicola J Sunter
A1 Claire Elstob
A1 Yaobo Xu
A1 Catherine Park
A1 Anne Quante
A1 Konstantin Strauch
A1 Christian Gieger
A1 Andrew Skol
A1 Thahira Rahman
A1 Lara Sucheston-Campbell
A1 Junke Wang
A1 Theresa Hahn
A1 Alyssa I Clay-Gilmour
A1 Gail L Jones
A1 Helen J Marr
A1 Graham H Jackson
A1 Tobias Menne
A1 Mathew Collin
A1 Adam Ivey
A1 Robert K Hills
A1 Alan K Burnett
A1 Nigel H Russell
A1 Jude Fitzgibbon
A1 Richard A Larson
A1 Michelle M Le Beau
A1 Wendy Stock
A1 Olaf Heidenreich
A1 Abrar Alharbi
A1 David J Allsup
A1 Richard S Houlston
A1 Jean Norden
A1 Anne M Dickinson
A1 Elisabeth Douglas
A1 Clare Lendrem
A1 Ann K Daly
A1 Louise Palm
A1 Kim Piechocki
A1 Sally Jeffries
A1 Martin Bornhäuser
A1 Christoph Röllig
A1 Heidi Altmann
A1 Leo Ruhnke
A1 Desiree Kunadt
A1 Lisa Wagenführ
A1 Heather J Cordell
A1 Rebecca Darlay
A1 Mette K Andersen
A1 Maria C Fontana
A1 Giovanni Martinelli
A1 Giovani Marconi
A1 Miguel A Sanz
A1 José Cervera
A1 Inés Gómez-Seguí
A1 Thomas Cluzeau
A1 Chimène Moreilhon
A1 Sophie Raynaud
A1 Heinz Sill
A1 Maria Teresa Voso
A1 Francesco Lo-Coco
A1 Hervé Dombret
A1 Meyling Cheok
A1 Claude Preudhomme
A1 Rosemary E Gale
A1 David Linch
A1 Julia Gaal-Wesinger
A1 Andras Masszi
A1 Daniel Nowak
A1 Wolf-Karsten Hofmann
A1 Amanda Gilkes
A1 Kimmo Porkka
A1 Jelena D Milosevic Feenstra
A1 Robert Kralovics
A1 David Grimwade
A1 Manja Meggendorfer
A1 Torsten Haferlach
A1 Szilvia Krizsán
A1 Csaba Bödör
A1 Friedrich Stölzel
A1 Kenan Onel
A1 James M Allan
YR 2021
UL http://medrxiv.org/content/early/2021/07/23/2021.07.22.21259893.abstract
AB Acute myeloid leukemia (AML) is a hematological malignancy with an undefined heritable risk. Here we performed a meta-analysis of three genome-wide association studies, with replication in a fourth study, incorporating a total of 4018 AML cases and 10488 controls. We identified a genome-wide significant risk locus for AML at 11q13.2 (rs4930561; P = 2.15 × 10-8; KMT5B). We also identified a genome-wide significant risk locus for the cytogenetically normal AML sub-group (N=1287) at 6p21.32 (rs3916765; P = 1.51 × 10-10; HLA). Our results inform on AML etiology by identifying putative functional genes operating in histone methylation (KMT5B) and immune function (HLA).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Blood Cancer UK (to JMA; #06002 and #13044). The Hungarian AML study was funded by the Hungarian National Research, Development and Innovation Office (NKFIH) (NVKP_16 1 2016 0004), a Momentum grant (LP 95021) from the Hungarian Academy of Sciences and EUs Horizon 2020 research and innovation program under grant agreement No. 739593. The KORA study was initiated and financed by the Helmholtz Zentrum Munchen, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ. The recruitment of cases via the Catholic University of Rome was funded by Progetto AIRC 5permille Mynerva. DN is an endowed Professor of the Deutsche Jose Carreras Leukaemie Stiftung (DJCLS H 03/01) and is funded by the H.W. & J. Hector fund, Baden Wuerttemberg and the Dr. Rolf M. Schwiete Fund, Mannheim.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were conducted in accordance with the Declaration of Helsinki and received local institutional review board or national Research ethics committee approval was given to the Newcastle Haematology Biobank (07/H0906/109+5) and the AML genome-wide association study in the UK (06/q1108/92, BH136664 (7078)). AML cases and controls for Samples from the Hungarian AML patients were obtained during the standard diagnostic workup at the Hematology Divisions of the 1st and 3rd Department of Internal Medicine, Semmelweis University, Budapest, following ethical approval from the Local Ethical Committee (TUKEB-1552012) and the Hungarian Medical Research Council (1483-2/2017/EKU).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAML case and control genotyping data from the UK Biobank can be obtained via application through http://www.ukbiobank.ac.uk/. Genotyping data on 2699 individuals recruited to the 1958 British Birth Cohort (Hap1.2M-Duo Custom array data) and 2501 individuals from the UK Blood Service are available from the Wellcome Trust Case Control Consortium 2 (http://www.wtccc.org.uk/;WTCCC2:EGAD00000000022, EGAD00000000024). Case and control genotyping data from 1615 individuals recruited to the KORA study can be obtained via application through https://www.helmholtz-muenchen.de/en/kora/. Other genotyping data supporting the findings of this study can be found as deposited in NCBI Gene Expression Omnibus under accession numbers GSE20672, GSE32462, GSE34542, GSE46745 and GSE46951 or from the authors on reasonable request. eQTL data is available from the eQTLGen consortium via http://www.eqtlgen.org/cis-eqtls.html. ENCODE data is available via download from ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/wgEncodeAwgSegmentationCombinedH1hesc.txt.gz for H1 human embryonic stem cells (H1hesc) and from ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/wgEncodeAwgSegmentationCombinedK562.txt.gz for K562 myeloid leukemia cells. The remaining data are contained within the supplementary files or available from the authors upon reasonable request.